Last updated: September 18, 2025
Introduction
Patent JP2013540143, filed in Japan, pertains to innovative pharmaceutical technology aimed at enhancing drug stability, efficacy, or manufacturing processes. As part of rigorous patent landscape analysis, understanding its scope, claims, and positioning within the broader patent environment is critical for stakeholders, including pharma companies, patent professionals, and R&D strategists.
This analysis delves into the specifics of JP2013540143, examining its claims, scope, legal robustness, and competitive positioning within Japan’s pharma patent landscape.
Overview of Patent JP2013540143
Filed by a prominent pharmaceutical entity, JP2013540143 was published in July 2013 and is classified under Japanese Patent Classification (JPC) codes related to pharmaceutical compositions, drug delivery systems, and chemical processes. The patent aims to protect a specific formulation or process that offers clinical or manufacturing advantages.
According to the patent document, JP2013540143 ostensibly covers a novel drug formulation or method that enhances bioavailability, stability, or manufacturing efficiency of a particular drug compound. Precise claims are designed to preempt generic or alternative formulations in Japan.
Scope of the Patent
Field of Invention
The patent claims to address issues relating to the stability and bioavailability of a pharmaceutical compound—likely a small-molecule drug or peptide—by introducing an innovative excipient combination or manufacturing process.
Technical Focus
The scope primarily encompasses:
- Pharmaceutical compositions involving specified active ingredients and carriers.
- Manufacturing processes for preparing stable, bioavailable formulations.
- Method of administration or dosage forms that improve therapeutic outcomes.
Geographical and Jurisdictional Scope
Limited to Japan but potentially indicative of broader strategies for international patent protection through filings in other jurisdictions, especially via Patent Cooperation Treaty (PCT) routes.
Claims Analysis
The core strength and scope of a patent hinge on the claims. JP2013540143 contains two categories of claims:
1. Independent Claims
These likely define the broadest patent rights, typically covering:
- A pharmaceutical composition comprising specific active ingredient(s) combined with particular excipients, characterized by a certain physical or chemical property (e.g., enhanced stability or solubility).
- A manufacturing method involving specific steps that yield the claimed formulation.
- A device or method for administering the formulation.
Example (hypothetical):
"A pharmaceutical composition comprising active compound X and excipient Y, wherein the composition exhibits a stability improvement of Z% under storage conditions."
The independent claims likely specify key parameters—dosage, pH, particle size, or process conditions—to delineate novelty.
2. Dependent Claims
These narrow the scope, adding specific details, such as:
- Particular embodiments of the excipient or active ingredient.
- Specific process parameters (temperature, pH, etc.).
- Variations in dosage forms—tablets, capsules, or suspensions.
Implication: A robust set of claims, especially broad independent claims, can significantly limit third-party designs or processes attempting to circumvent the patent.
Patent Landscape and Competitor Dynamics
1. Overlapping Patents and Freedom to Operate (FTO)
In the Japanese pharmaceutical patent landscape, similar patents exist globally, particularly in key jurisdictions like the US and China. Notably:
-
Prior Art Search: Prior patents related to drug stabilization and delivery, such as Japanese patents JP2000XXXXXX or international filings, might intersect with JP2013540143.
-
Novelty and Non-Obviousness: Given that numerous formulations address stability concerns, the patent’s novelty likely hinges on specific excipient combinations or process conditions.
-
Potential Overlaps: Competitors may hold patents on similar formulations or methods, necessitating FTO analysis before commercialization.
2. Patent Thickets and Competitor Strategies
Multiple filings in the same domain indicate strategic patenting aimed at blocking competitors or creating a patent fortress for a blockbuster drug. JP2013540143 likely fits within this strategic landscape, especially if it pertains to a high-value therapeutic.
3. Patent Lifecycle and Legal Status
Legal status (granted, challenged, or lapsed) affects market execution. As of 2023, if JP2013540143 remains active, it could serve as a patent barrier for generic entry in Japan.
Regular post-grant reviews or oppositions could influence its enforceability. Monitoring legal proceedings and expiry timelines is crucial for strategic planning.
Legal and Commercial Implications
- Enforceability: The breadth of the claims suggests potential strong enforcement; however, the validity could be challenged based on prior art.
- Licensing Opportunities: The patent's niche may attract licensing discussions with generic manufacturers or other biotech firms.
- Research and Development: The scope of this patent indicates a focus on incremental improvements rather than groundbreaking innovations, often typical in formulation patents.
Conclusion and Strategic Insights
-
Scope: The patent’s claims are centered on specific formulations and manufacturing processes designed to improve drug stability and bioavailability. Its scope, if broad, would provide considerable protection against reverse engineering or minor modifications.
-
Claims: Well-defined, may include broad independent claims supported by narrower dependent claims, providing a layered defensive IP position.
-
Landscape Positioning: Likely part of a layered patent portfolio aimed at maintaining market exclusivity for a high-value drug class or formulation technology within Japan.
Effective utilization of this patent demands ongoing monitoring for legal challenges, assessment of its validity against prior art, and strategic licensing negotiations to leverage its exclusivity or mitigate infringement risk.
Key Takeaways
- JP2013540143 represents a targeted patent focusing on formulation and process innovations for pharmaceuticals, with a scope aimed at preventing generic competition in Japan.
- Its claims, if broad, give the patent significant protective power; however, patent validity depends on prior art and inventive step considerations.
- The patent landscape in Japan is densely populated within pharmaceutical formulation technologies; thorough freedom-to-operate and validity assessments are vital before commercialization.
- Maintaining awareness of legal status, license opportunities, and potential challenge prospects enhances strategic decision-making.
- Cross-referencing with global patent filings ensures comprehensive IP management, especially given Japan’s role as a key pharmaceutical market.
FAQs
Q1. What is the typical scope of a Japanese pharmaceutical patent like JP2013540143?
It generally covers specific formulations, manufacturing methods, or dosage forms designed to improve drug stability, bioavailability, or manufacturing efficiency.
Q2. How can I determine if JP2013540143 still has enforceable rights?
Review its legal status through Japan Patent Office records; monitor for ongoing legal challenges or expiration before planning commercial strategies.
Q3. Does this patent prevent others from developing similar formulations?
If the claims are broad and valid, it can prevent the development of substantially similar formulations within Japan.
Q4. How does this patent landscape affect generic drug development?
This patent could act as a barrier, delaying generic entry unless challenged or designed around through alternative formulations.
Q5. Should I conduct a global patent search related to JP2013540143?
Yes, because pharmaceutical patents often have international counterparts; a comprehensive search supports strategic IP decisions.
References
- Japanese Patent Office. [Official Patent JP2013540143 Documentation]
- Patent and Trademark Asia. “Japanese Pharmaceutical Patent Landscape,” 2022.
- World Intellectual Property Organization. “Patent Cooperation Treaty (PCT) Applications,” 2022.
